C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

C4X Discovery Holdings PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

C4X Discovery Holdings PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
C4X Discovery Holdings PLC
LSE:C4XD
Revenue
ÂŁ24.7m
CAGR 3-Years
N/A
CAGR 5-Years
28%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Revenue
ÂŁ169.7m
CAGR 3-Years
14%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Revenue
ÂŁ23.7m
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Revenue
ÂŁ272k
CAGR 3-Years
-30%
CAGR 5-Years
-40%
CAGR 10-Years
-26%
Ergomed PLC
LSE:ERGO
Revenue
ÂŁ152.1m
CAGR 3-Years
27%
CAGR 5-Years
25%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Revenue
ÂŁ64.4m
CAGR 3-Years
22%
CAGR 5-Years
64%
CAGR 10-Years
41%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

What is C4X Discovery Holdings PLC's Revenue?
Revenue
24.7m GBP

Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Revenue amounts to 24.7m GBP.

What is C4X Discovery Holdings PLC's Revenue growth rate?
Revenue CAGR 5Y
28%

Over the last year, the Revenue growth was 473%.

Back to Top